Dihexa vs Orexin B
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin IV, engineered at Washington State University to be orally active and to cross into the brain. The pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. The reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in April 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation.
Also: Hypocretin-2, Hcrt-2
Orexin B (hypocretin-2) is the sister peptide of orexin A. Both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. Orexin B is a 28-amino-acid linear peptide that mostly acts through the OX2R receptor, the receptor most tied to narcolepsy. The catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Dihexa | Orexin B |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dihexa is derived from angiotensin IV, a fragment of the renin-angiotensin system that has long been linked to memory in animal work. The leading hypothesis is that it acts on the hepatocyte growth factor (HGF) and its receptor c-Met, a growth-factor system that drives the formation of new dendritic spines and synapses. In cultured hippocampal neurons, dihexa and related angiotensin IV analogs increase spine density, and that effect disappears when the HGF/c-Met system is blocked, which is the main evidence the pathway matters. It is worth being blunt that the exact molecular interaction has been contested, since the original paper proposing direct HGF binding was retracted, so the mechanism is best treated as a working hypothesis rather than settled fact. | Orexin B binds OX2R about as strongly as orexin A does, but binds OX1R roughly 20 times more weakly, so it behaves as a relatively OX2R-preferring signal. OX2R is the receptor that matters most for staying awake and keeping REM sleep in its place: a broken OX2R gene causes inherited narcolepsy in dogs, and the newest approved narcolepsy drug is an OX2R agonist. Structurally, orexin B is a linear chain without the two disulfide bridges that make orexin A more stable. A 1999 mouse study found that injected orexin B was rapidly degraded in blood and none reached the brain intact, while orexin A crossed easily. That is the main reason human research has focused on orexin A. |
| Common Dosing | 5-20 mg daily Once daily | No established human dose Not established |
| Administration | Oral, sublingual, or intranasal | Intracerebroventricular or local injection in animal studies |
| Typical Duration | Cycles of 2-4 weeks | Acute single-dose animal experiments |
| Best Time to Take | Morning | Not established |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The published evidence on dihexa is entirely preclinical. Harding, McCoy and colleagues at Washington State University reported that metabolically stabilized angiotensin IV analogs, including dihexa, restored cognition in scopolamine-impaired and aged rats (J Pharmacol Exp Ther, 2013; this paper carries a 2021 expression of concern but is not retracted). A 2014 JPET study tied the procognitive and synaptogenic effects to the HGF/c-Met system, but that paper was retracted in April 2025, together with the 2012 paper that first proposed dihexa as an HGF/Met modifier, after the journal had flagged them with expressions of concern in 2021. There are no registered human clinical trials and no published human safety or pharmacokinetic data, so dosing, long-term safety and whether any of the rodent benefit translates to people are all unknown. The often repeated 'millions of times more potent than BDNF' line comes from a single cell assay and should not be read as a clinical fact. Treat dihexa as a research molecule with interesting but shaken animal data, not as a proven cognitive enhancer. | Orexin B has been studied for almost 30 years, but almost entirely as a research tool in animals and tissue. The 1998 discovery paper in Cell (Sakurai and colleagues) showed both orexins increased food intake when injected into rat brains. Work since then has mapped its role in arousal, feeding, and more recently pain: 2026 mouse research found orexin B acting at OX2R could trigger migraine-like headache pain in male but not female mice. We could not find any published study giving orexin B to humans, by nose or by injection, and no registered clinical trials. If you want the orexin story with actual human data, see orexin A. Orexin B on its own is a preclinical compound with a real biological role and no tested human use. |
Frequently Asked Questions: Dihexa vs Orexin B
What is the difference between Dihexa and Orexin B?
Dihexa is a cognitive peptide that dihexa (n-hexanoic-tyr-ile-(6) aminohexanoic amide) is a small synthetic peptide built from angiotensin iv, engineered at washington state university to be orally active and to cross into the brain. the pitch is bold: it is studied as a procognitive compound that may rebuild synaptic connections, and lab claims of extreme potency made it a darling of the nootropic underground. the reality check: every supporting study is in cells or rodents, there are zero human clinical trials, and in april 2025 the journal retracted two of the key papers behind its proposed mechanism (2012 and 2014) after a university investigation. Orexin B is a cognitive peptide that orexin b (hypocretin-2) is the sister peptide of orexin a. both are cut from the same precursor protein in the hypothalamus and both help regulate wakefulness and appetite. orexin b is a 28-amino-acid linear peptide that mostly acts through the ox2r receptor, the receptor most tied to narcolepsy. the catch for anyone hoping to use it: it falls apart fast in the blood, barely reaches the brain from the bloodstream, and has never been given to humans in a published study. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dihexa or Orexin B?
Neither is universally "better" - the choice depends on your specific goals. Dihexa is typically used for cognitive purposes, while Orexin B is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dihexa and Orexin B be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dihexa and Orexin B together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.